博雅生物：公司已确定聚焦血液制品的发展战略，对于非血液制品业务将适时进行处置或剥离

Group 1 - The core viewpoint of the article is that Boya Bio-Pharmaceutical (300294.SZ) has confirmed its strategic focus on the development of blood products and plans to dispose of or divest its non-blood product business at an appropriate time [2][3] - The company has stated that it will fulfill its information disclosure obligations promptly if there are any developments regarding the disposal or divestment of its non-blood product business [2]